Circle Pharma
Highly Engaged Employees
Highly Engaged EmployeesBusiness Services · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
681 Gateway Blvd Fl 3, South San Francis...Phone Number
(650) 825-4099Website
www.circlepharma.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
2
1
2
1
1
About Circle Pharma
Circle Pharma operates an indication-agnostic discovery engine for the development of cell permeable macro-cyclic peptide therapeutics. We deploy our computational structure-based design approach against important therapeutic targets that are challenging to address with conventional small molecules. The company was founded in 2012 and is headquartered in San Francisco, California.Explore more
Circle Pharma Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Circle Pharma your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if Circle Pharma has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Circle Pharma recently announced quarterly report
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Circle Pharma launches new products
Click to see if Circle Pharma had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Circle Pharma
Circle Pharma, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once Circle Pharma has new funding data
Check out if Circle Pharma is spiking on competitors!
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to Circle Pharma
Compare insights from companies similar to Circle Pharma, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Circle Pharma is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Circle Pharma is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Circle Pharma.
Circle Pharma financials insights
Gather financial insights about Circle Pharma, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2016
Series A
$3.8M
2020
Series B
$45M
2021
Series C
$66M
2024
Series D
$90M
Circle Pharma Tech Stack
A closer look at the technologies used by Circle Pharma
Most Recent Scoops
Person-Based
Medical Research, Pharmaceuticals
Person-Based
Events, Finance, Investor Relations
Person-Based
Person-Based
New Hire
Executive Move
Executive Moves, New Hire
Circle Pharma News & Media
Circle Pharma Appoints Rob Lauzen as Chief Financial Officer - Bluefield Daily Telegraph
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Nov 3, 2025--Circle Pharma Appoints Rob Lauzen as Chief Financial Officer - Yahoo Finance
SOUTH SAN FRANCISCO, Calif., November 03, 2025--Circle Pharma, Inc., a clinical-stage biopharmaceutical company pioneering next-generation targeted macrocycle therapeutics for cancer, today announced the appointment of Rob Lauzen as chief financial officer. Mr. Lauzen brings deep financial expertise and broad experience within the life sciences industry, having most recently served as chief financial officer of Prilenia Therapeutics, where he oversaw all aspects of the company’s capital strategyCircle Pharma Receives FDA Orphan Drug Designation for CID-078 for the Treatment of Small Cell Lung Cancer
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- #Biotech--Circle Pharma, a clinical-stage biopharmaceutical company advancing macrocycle therapeutics for difficult-to-treat cancers, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to CID-078 for the treatment of small cell lung cancer (SCLC). Small-cell lung cancer is a highly aggressive form of lung cancer that accounts for approximately 13–15% of all lung cancer cases1 and is strongly liCircle Pharma to Present Trials in Progress Poster on CID-078, a First-in-Class Cyclin A/B Inhibitor, at the ASCO 2025 Annual Meeting
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- #ASCO2025--Circle Pharma, a clinical-stage biopharmaceutical company advancing macrocycle therapeutics for difficult-to-treat cancers, today announced that its Trials in Progress abstract has been selected for poster presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 30 to June 3 in Chicago. The poster will showcase the design and ongoing progress of its Phase 1 study of CID-078 (NCT06577987), a fir
Read more news
Top Business Services Companies
Top companies in Australia by revenue
Frequently Asked Questions Regarding Circle Pharma
Sign Up For FreeTo access detailed company insights
Circle Pharma operates an indication-agnostic discovery engine for the development of cell permeable macro-cyclic peptide therapeutics. We deploy our computational structure-based design approach against important therapeutic targets that are challenging to address with conventional small molecules. The company was founded in 2012 and is headquarte... Read More
